Clinical Trial Update: Open Label, Dose Escalation Phase I Study of AZD2281 [Phase 1]

View source ↗

Summary

This document summarizes an open-label, dose-escalation Phase I trial of AZD2281 (olaparib) in patients with advanced solid tumors, focusing on safety, tolerabi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• AZD2281 (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced Solid Malignancies | Phase 1 | Status: COMPLETED